Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma

Lucia Brambilla, A. Miedico, S. Ferrucci, A. Romanelli, M. Brambati, M. Vinci, L. Tedeschi, V. Boneschi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Classic KS (CKS) mainly affects elderly people, has an irregular course, and is relatively benign for years. However, sometimes the disease may progress rapidly and spread to internal organs, thus necessitating systemic chemotherapy. We therefore decided to carry out a prospective trial using vinblastine and bleomycin, which are active, easy to administer and control, and low cost. Methods: We treated 29 patients affected by CKS with vinblastine i.v., up to 10 mg in combination with bleomycin i.m., 15 IU every 3 weeks. We administered a median of seven cycles of therapy. Results: All the 29 enrolled patients were evaluated: 21% reached a complete response and 76% had an intermediate response. Toxicity was limited. The maximal response was attained in a median of 5 months, with a mean duration of 4 months. Conclusion: The combination of vinblastine and bleomycin achieved a high rate of objective responses in a subgroup of elderly and symptomatic patients, without considerable toxicity. We recommend the combination as first line chemotherapy for advanced CKS.

Original languageEnglish
Pages (from-to)1090-1094
Number of pages5
JournalJournal of the European Academy of Dermatology and Venereology
Volume20
Issue number9
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Vinblastine
Kaposi's Sarcoma
Bleomycin
Drug Therapy
Cost Control
Therapeutics

Keywords

  • Bleomycin
  • Chemotherapy
  • Kaposi's sarcoma
  • Vinblastine

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma. / Brambilla, Lucia; Miedico, A.; Ferrucci, S.; Romanelli, A.; Brambati, M.; Vinci, M.; Tedeschi, L.; Boneschi, V.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 20, No. 9, 10.2006, p. 1090-1094.

Research output: Contribution to journalArticle

Brambilla, Lucia ; Miedico, A. ; Ferrucci, S. ; Romanelli, A. ; Brambati, M. ; Vinci, M. ; Tedeschi, L. ; Boneschi, V. / Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma. In: Journal of the European Academy of Dermatology and Venereology. 2006 ; Vol. 20, No. 9. pp. 1090-1094.
@article{d283b21471584330adda481bdfe80b4e,
title = "Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma",
abstract = "Background: Classic KS (CKS) mainly affects elderly people, has an irregular course, and is relatively benign for years. However, sometimes the disease may progress rapidly and spread to internal organs, thus necessitating systemic chemotherapy. We therefore decided to carry out a prospective trial using vinblastine and bleomycin, which are active, easy to administer and control, and low cost. Methods: We treated 29 patients affected by CKS with vinblastine i.v., up to 10 mg in combination with bleomycin i.m., 15 IU every 3 weeks. We administered a median of seven cycles of therapy. Results: All the 29 enrolled patients were evaluated: 21{\%} reached a complete response and 76{\%} had an intermediate response. Toxicity was limited. The maximal response was attained in a median of 5 months, with a mean duration of 4 months. Conclusion: The combination of vinblastine and bleomycin achieved a high rate of objective responses in a subgroup of elderly and symptomatic patients, without considerable toxicity. We recommend the combination as first line chemotherapy for advanced CKS.",
keywords = "Bleomycin, Chemotherapy, Kaposi's sarcoma, Vinblastine",
author = "Lucia Brambilla and A. Miedico and S. Ferrucci and A. Romanelli and M. Brambati and M. Vinci and L. Tedeschi and V. Boneschi",
year = "2006",
month = "10",
doi = "10.1111/j.1468-3083.2006.01730.x",
language = "English",
volume = "20",
pages = "1090--1094",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "9",

}

TY - JOUR

T1 - Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma

AU - Brambilla, Lucia

AU - Miedico, A.

AU - Ferrucci, S.

AU - Romanelli, A.

AU - Brambati, M.

AU - Vinci, M.

AU - Tedeschi, L.

AU - Boneschi, V.

PY - 2006/10

Y1 - 2006/10

N2 - Background: Classic KS (CKS) mainly affects elderly people, has an irregular course, and is relatively benign for years. However, sometimes the disease may progress rapidly and spread to internal organs, thus necessitating systemic chemotherapy. We therefore decided to carry out a prospective trial using vinblastine and bleomycin, which are active, easy to administer and control, and low cost. Methods: We treated 29 patients affected by CKS with vinblastine i.v., up to 10 mg in combination with bleomycin i.m., 15 IU every 3 weeks. We administered a median of seven cycles of therapy. Results: All the 29 enrolled patients were evaluated: 21% reached a complete response and 76% had an intermediate response. Toxicity was limited. The maximal response was attained in a median of 5 months, with a mean duration of 4 months. Conclusion: The combination of vinblastine and bleomycin achieved a high rate of objective responses in a subgroup of elderly and symptomatic patients, without considerable toxicity. We recommend the combination as first line chemotherapy for advanced CKS.

AB - Background: Classic KS (CKS) mainly affects elderly people, has an irregular course, and is relatively benign for years. However, sometimes the disease may progress rapidly and spread to internal organs, thus necessitating systemic chemotherapy. We therefore decided to carry out a prospective trial using vinblastine and bleomycin, which are active, easy to administer and control, and low cost. Methods: We treated 29 patients affected by CKS with vinblastine i.v., up to 10 mg in combination with bleomycin i.m., 15 IU every 3 weeks. We administered a median of seven cycles of therapy. Results: All the 29 enrolled patients were evaluated: 21% reached a complete response and 76% had an intermediate response. Toxicity was limited. The maximal response was attained in a median of 5 months, with a mean duration of 4 months. Conclusion: The combination of vinblastine and bleomycin achieved a high rate of objective responses in a subgroup of elderly and symptomatic patients, without considerable toxicity. We recommend the combination as first line chemotherapy for advanced CKS.

KW - Bleomycin

KW - Chemotherapy

KW - Kaposi's sarcoma

KW - Vinblastine

UR - http://www.scopus.com/inward/record.url?scp=33748888637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748888637&partnerID=8YFLogxK

U2 - 10.1111/j.1468-3083.2006.01730.x

DO - 10.1111/j.1468-3083.2006.01730.x

M3 - Article

C2 - 16987264

AN - SCOPUS:33748888637

VL - 20

SP - 1090

EP - 1094

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 9

ER -